Five Minutes in Healthcare is where I discuss current events with some of the industry's most influential leaders.
Today I am joined by John Zehner, CEO of SpectronRx, for a conversation about the radiopharmaceutical Actinium-225. His company recently completed initial construction
on a production facility in Bunker Hill, Indiana.
We talk about the unique advantages of Actinium-225 as a cancer therapeutic, the difference between alpha and beta isotopes, and the role SpectronRx is playing in distributing these agents to the patients who stand to benefit most from them.